19 min.
NET Doctors Discuss Highlights from ASCO2024 NETCast
-
- Geneeskunde
Dr. Simron Singh is a medical oncologist, affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute, and an assistant professor at the University of Toronto. Dr. Singh is a longtime member of NANETS and the current Treasurer of its Board of Directors.
Dr. Alexandria T. Phan is a Professor of Internal Medicine and Medical Oncology at Froedtert & Medical College of Wisconsin, with a special focus on neuroendocrine tumors and malignancies of the GI tract. Dr. Phan is a member of NANETS' Communications and the moderator of this discussion. The doctors will discuss highlights from the recent ASCO meeting, with a special focus on the results of the phase 3 randomized NETTER-2 study. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Dr. Simron Singh is a medical oncologist, affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute, and an assistant professor at the University of Toronto. Dr. Singh is a longtime member of NANETS and the current Treasurer of its Board of Directors.
Dr. Alexandria T. Phan is a Professor of Internal Medicine and Medical Oncology at Froedtert & Medical College of Wisconsin, with a special focus on neuroendocrine tumors and malignancies of the GI tract. Dr. Phan is a member of NANETS' Communications and the moderator of this discussion. The doctors will discuss highlights from the recent ASCO meeting, with a special focus on the results of the phase 3 randomized NETTER-2 study. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
19 min.